Cancer stem cells, CD200 and immunoevasion

Trends in Immunology

Volumn 29, Issue 10, 2008, Pages 464-468

  Kawasaki, Brian T ^a   Farrar, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARBOPLATIN; CD133 ANTIGEN; CD200 ANTIGEN; ETOPOSIDE; HERMES ANTIGEN; PACLITAXEL; TEMOZOLOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CARCINOGENICITY; COLON CANCER; GLIOMA; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTHERAPY; KIDNEY CARCINOMA; LUNG CANCER; LYMPHATIC LEUKEMIA; MALIGNANT MESOTHELIOMA; MELANOMA; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROGNOSIS; PROSTATE CANCER; TESTIS CANCER; TUMOR IMMUNITY; TUMOR IMMUNOLOGY;

ANIMALS; CERAMICS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR ESCAPE;

EID: 52249118343     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2008.07.005     Document Type: Article

References (47)

1. Restifo N.P., and Rosenberg S.A. Use of standard criteria for assessment of cancer vaccines. Lancet Oncol. 6 (2005) 3-4
2. Rosenberg S.A., et al. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10 (2004) 909-915
3. Gajewski T.F., et al. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213 (2006) 131-145
4. Kvinlaug B.T., and Huntly B.J. Targeting cancer stem cells. Expert Opin. Ther. Targets 11 (2007) 915-927
5. Tang D.G., et al. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol. Carcinog. 46 (2007) 1-14
6. Sell S. Stem cell origin of cancer and differentiation therapy. Crit. Rev. Oncol. Hematol. 51 (2004) 1-28
7. Pardal R., et al. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 3 (2003) 895-902
8. Lapidot T., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 (1994) 645-648
9. Al-Hajj M. Cancer stem cells and oncology therapeutics. Curr. Opin. Oncol. 19 (2007) 61-64
10. Li C., et al. Identification of pancreatic cancer stem cells. Cancer Res. 67 (2007) 1030-1037
11. Ailles L.E., and Weissman I.L. Cancer stem cells in solid tumors. Curr. Opin. Biotechnol. 18 (2007) 460-466
12. Liu R., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356 (2007) 217-226
13. Bao S., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (2006) 756-760
14. Zeppernick F., et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 14 (2008) 123-129
15. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5 (2005) 263-274
16. Nathan C., and Muller W.A. Putting the brakes on innate immunity: a regulatory role for CD200?. Nat. Immunol. 2 (2001) 17-19
17. Kretz-Rommel A., et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J. Immunol. 178 (2007) 5595-5605
18. Webb M., and Barclay A.N. Localisation of the MRC OX-2 glycoprotein on the surfaces of neurones. J. Neurochem. 43 (1984) 1061-1067
19. Barclay A.N., et al. Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure. Biochem. Soc. Symp. 51 (1986) 149-157
20. Wright G.J., et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J. Immunol. 171 (2003) 3034-3046
21. Bukovsky A., et al. The localization of Thy-1.1, MRC OX 2 and Ia antigens in the rat ovary and fallopian tube. Immunology 48 (1983) 587-596
22. Hoek R.M., et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290 (2000) 1768-1771
23. Rosenblum M.D., et al. Expression of CD200 on epithelial cells of the murine hair follicle: a role in tissue-specific immune tolerance?. J. Invest. Dermatol. 123 (2004) 880-887
24. Rosenblum M.D., et al. CD200, a 'no danger' signal for hair follicles. J. Dermatol. Sci. 41 (2006) 165-174
25. Gorczynski R.M., et al. Induction of tolerance-inducing antigen-presenting cells in bone marrow cultures in vitro using monoclonal antibodies to CD200R. Transplantation 77 (2004) 1138-1144
26. Gorczynski R.M., et al. Augmented Induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R. Transplantation 79 (2005) 1180-1183
27. Gorczynski R.M., et al. An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. J. Immunol. 163 (1999) 1654-1660
28. Jenmalm M.C., et al. Regulation of myeloid cell function through the CD200 receptor. J. Immunol. 176 (2006) 191-199
29. Cherwinski H.M., et al. The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J. Immunol. 174 (2005) 1348-1356
30. Zhang S., et al. Molecular mechanisms of CD200 inhibition of mast cell activation. J. Immunol. 173 (2004) 6786-6793
31. Siva A., et al. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol. Immunother. 57 (2007) 987-996
32. Kawasaki B.T., et al. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem. Biophys. Res. Commun. 364 (2007) 778-782
33. Moreaux J., et al. CD200: a putative therapeutic target in cancer. Biochem. Biophys. Res. Commun. 366 (2008) 117-122
34. Moreaux J., et al. CD200 is a new prognostic factor in multiple myeloma. Blood 108 (2006) 4194-4197
35. Tonks A., et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21 (2007) 566-568
36. Gorczynski R.M., et al. Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice. Clin. Exp. Immunol. 126 (2001) 220-229
37. Takeuchi T., et al. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma. Cancer Immunol. Immunother. 43 (1997) 375-381
38. Filella X., et al. Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate 44 (2000) 271-274
39. Lauerova L., et al. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 49 (2002) 159-166
40. McWhirter J.R., et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 1041-1046
41. Ohyama M., et al. Characterization and isolation of stem cell-enriched human hair follicle bulge cells. J. Clin. Invest. 116 (2006) 249-260
42. Ossendorp F., et al. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187 (1998) 693-702
43. Lowes M.A., et al. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J. Invest. Dermatol. 108 (1997) 914-919
44. Aruga A., et al. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression. J. Leukoc. Biol. 61 (1997) 507-516
45. Dalerba P., et al. Cancer stem cells: models and concepts. Annu. Rev. Med. 58 (2007) 267-284
46. Liu G., et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 5 (2006) 67
47. Dean M., et al. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5 (2005) 275-284